New York city New York vaccine medicines New York city New York

Pfizer swings to a profit, but misses Street expectations

Reading now: 285
www.clickorlando.com

NEW YORK – Pfizer swing to a small profit in the fourth-quarter as rising medicine sales helped offset big increases in spending on research and production, but it still missed Wall Street expectations.

The New York drugmaker, the first company to get U.S. emergency use authorization for a COVID-19 vaccine, reported fourth-quarter net income of $594 million, or 10 cents per share.

A year earlier, Pfizer posted a loss of $337 million, or 6 cents per share, mainly due to a big writedown on the value of eczema drug Eucrisa.

Excluding one-time items, adjusted earnings came to 42 cents per share, or 4 cents shy of Wall Street projections, according to a survey by Zacks Investment Research.

Read more on clickorlando.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA